New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
07:22 EDTSUPNSupernus price target raised to $14 from $12 at Stifel
After Supernus stated that it believes it is on track to reach cash flow break-even, Stifel thinks the launches of the company's Oxtellar and Trokendi drugs are going well. Stifel believes that uptake of the company's Trokendi XR drug could improve, and it keeps a Buy rating on the stock.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
10:57 EDTSUPNSupernus management to meet with Jefferies
Subscribe for More Information
September 22, 2014
18:18 EDTSUPNOn The Fly: After Hours Movers
Subscribe for More Information
16:21 EDTSUPNSupernus to explore 'broad range of strategic opportunities'
Supernus Pharmaceuticals is providing the following business update in light of recent investor filings with the SEC: "The company will explore a broad range of strategic opportunities. This includes in-licensing products and entering into co-promotion partnerships which are synergistic with our neurology sales force call point, potential co-development partnerships on our pipeline products, and growth opportunities through value-creating and transformative merger and acquisition transactions."
16:20 EDTSUPNSupernus reaffirms it is on track to become cash flow breakeven by year-end
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use